As mentioned above, prostate cancer (PC), luminal breast cancer (LBC), and small intestine neuroendocrine tumors (SI-NET) are the cancer subtypes in which CDKN1B mutations have been identified as driver genetic lesions in a significant percentage of cases (Supplementary Table 1). The gene discussed is CDKN1B; the disease is prostate carcinoma.